IHH hospitals install advanced pathogen identification system

The system is installed in IHH Healthcare’s Gleneagles, Mount Elizabeth, and Mount Elizabeth Novena hospitals.

Three IHH Healthcare hospitals in Singapore installed QIAstat-Dx syndromic testing system, which is expected to enhance pathogen identification.

Parkway Laboratories, in partnership with Netherlands-based biomedical solutions firm Qiagen, installed the system on IHH Healthcare’s Gleneagles, Mount Elizabeth, and Mount Elizabeth Novena hospitals.

It is expected to enhance patient management by optimizing syndromic testing diagnosis and treatment with accurate pathogen identification. 

QIAstat-Dx employs single-use cartridges with built-in sample processing and on-board reagents. It detects and differentiates between multiple pathogens, with results in about an hour, providing rapid answers for the detection of a wide range of infections.

The disease area panels include the QIAstat-Dx Respiratory SARS-CoV-2 Panel, QIAstat-Dx Gastrointestinal Panel, and QIAstat-Dx Meningitis/Encephalitis Panel.

“By providing fast and accurate syndromic testing solutions across respiratory, gastrointestinal, and central nervous system infections, we're enabling healthcare providers to make informed decisions quickly, potentially reducing unnecessary antibiotic use and supporting antimicrobial stewardship efforts,” said William Lin, senior director, commercial operation, APEC at QIAGEN.

The agreement expands a previous collaboration between QIAGEN and Parkway Laboratories for latent tuberculosis infection screening using QuantiFERON-TB Gold Plus.